<div id="readability-page-1"><p>Fayez Sarofim &amp; Co lowered its holdings in shares of  Abbott Laboratories (NYSE:ABT - Free Report) by 2.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The fund owned 4,522,297 shares of the healthcare product maker's stock after selling 99,447 shares during the quarter. Abbott Laboratories accounts for about  1.5% of Fayez Sarofim &amp; Co's portfolio, making the stock its 22nd largest position. Fayez Sarofim &amp; Co owned about 0.26% of Abbott Laboratories worth $619,107,000 as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>Abbott Laboratories</strong> alerts:</span></p></div><ul><li>ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat</li></ul><p>Several other hedge funds have also recently made changes to their positions in the business. IMG Wealth Management Inc. grew its position in  Abbott Laboratories by 759.1% in the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker's stock worth $26,000 after acquiring an additional 167 shares in the last quarter.  Elequin Capital LP bought a new stake in shares of  Abbott Laboratories in the 1st quarter valued at approximately $30,000.  Anfield Capital Management LLC boosted its holdings in shares of  Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker's stock worth $32,000 after purchasing an additional 104 shares during the period.  Curio Wealth LLC increased its position in shares of  Abbott Laboratories by 15,250.0% during the 2nd quarter. Curio Wealth LLC now owns 307 shares of the healthcare product maker's stock valued at $42,000 after purchasing an additional 305 shares during the last quarter.  Finally, Pineridge Advisors LLC raised its holdings in  Abbott Laboratories by 34.6% during the 2nd quarter. Pineridge Advisors LLC now owns 315 shares of the healthcare product maker's stock valued at $43,000 after buying an additional 81 shares during the period. 75.18% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Abbott Laboratories Stock Performance</h2><p>Shares of ABT stock opened at $121.88 on Tuesday. The firm has a market cap of $211.93 billion, a price-to-earnings ratio of 15.27, a PEG ratio of 2.28 and a beta of 0.71. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The company's 50 day moving average is $128.31 and its 200 day moving average is $130.72. </p><ul><li>Abbott Laboratories' October Price Plunge Is a Signal to Buy</li></ul><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.30. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The business had revenue of $11.37 billion for the quarter, compared to analysts' expectations of $11.40 billion. During the same quarter last year, the firm earned $1.21 EPS. The business's revenue for the quarter was up 6.9% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS.  On average, sell-side analysts anticipate that  Abbott Laboratories will post 5.14 EPS for the current fiscal year. </p><h2>Abbott Laboratories Dividend Announcement</h2><p>The company also recently announced a quarterly dividend, which was paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th were issued a $0.59 dividend. The ex-dividend date was Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.9%. Abbott Laboratories's payout ratio is currently 29.57%. </p><h2>Wall Street Analysts Forecast Growth</h2><ul><li>Why Abbott Laboratories Is a Q2 2025 Buy: Growth &amp; Yield</li></ul><p>A number of research analysts have weighed in on the stock. Raymond James Financial boosted their price objective on shares of Abbott Laboratories from $141.00 to $146.00 and gave the company an &#34;outperform&#34; rating in a research report on Thursday, October 16th. Daiwa Capital Markets upped their price target on shares of Abbott Laboratories from $134.00 to $136.00 and gave the company an &#34;outperform&#34; rating in a report on Tuesday, October 21st. Evercore ISI reduced their price objective on shares of Abbott Laboratories from $144.00 to $142.00 and set an &#34;outperform&#34; rating on the stock in a research report on Wednesday, October 15th. William Blair upgraded Abbott Laboratories to a &#34;strong-buy&#34; rating in a research report on Thursday, November 20th. Finally, Wells Fargo &amp; Company increased their price target on Abbott Laboratories from $142.00 to $146.00 and gave the stock an &#34;overweight&#34; rating in a report on Thursday, October 16th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have assigned  a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $147.00.</p><p><b>Check Out Our Latest Stock Report on Abbott Laboratories</b></p><h2>Abbott Laboratories Company Profile</h2> (Free Report)<p>Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Abbott Laboratories</li><li>How to Invest in Blue Chip Stocks</li><li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li><li>What is a Special Dividend?</li><li>3 Stocks Most Likely to Split in 2026</li><li>How to Invest in Small Cap Stocks </li><li>ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again</li></ul><p><strong>Want to see what other hedge funds are holding ABT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2><p>Before you consider Abbott Laboratories, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Fayez Sarofim & Co reduced its stake in Abbott Laboratories by 2.2% in Q2, selling 99,447 shares. Abbott's stock opened at $121.88, with a market cap of $211.93 billion. Analysts forecast growth, with price targets ranging from $134 to $146. Abbott's Q3 earnings met expectations, and the company announced a quarterly dividend of $0.59 per share. The stock is considered a buy for Q2 2025 due to growth and yield potential.</p>

Fayez Sarofim & Co Sells 99,447 Shares of Abbott Laboratories $ABT